Partnering
4mAb™ an unencumbered and independent platform
The 4mAb™ platform is unencumbered by patent or licensing restrictions and can be used to develop antibodies against any antigen target.
There are a number of partnering options available with 4-Antibody:
- Out-licensing or partnered development of 4mAb™ fully human antibodies in the 4-Antibody pipeline.
- Joint initiation of co-development projects for validated targets.
- Non-exclusive acquisition of the 4mAb™ discovery platform for development of in-house 4mAb™ based programmes against any and all targets.